Promoter Hypermethylation Profile of Kidney Cancer with New Proapoptotic p53 Target Genes and Clinical Implications
Frank Christoph(Charité - Universitätsmedizin Berlin), Mark Schrader(Arbeitsgemeinschaft Urologische Onkologie), Hans Krause(Charité - Universitätsmedizin Berlin), Martin Schostak(Aturo), Kurt Miller(Charité - Universitätsmedizin Berlin), Carsten Kempkensteffen(Charité - Universitätsmedizin Berlin), Steffen Weikert(St. Hedwig-Krankenhaus), Jens Köllermann
Cited by 56
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k